LAVA Therapeutics N.V. (LVTX)
$1.5491
Rating:
Recommendation:
-
| Symbol | LVTX |
|---|---|
| Price | $1.5491 |
| Beta | -0.390 |
| Volume Avg. | 0.03M |
| Market Cap | 40.724M |
| Shares () | - |
| 52 Week Range | 1.365-7.38 |
| 1y Target Est | - |
| DCF Unlevered | LVTX DCF -> | |
|---|---|---|
| DCF Levered | LVTX LDCF -> | |
| ROE | -51.14% | Strong Sell |
| ROA | -33.16% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 10.88% | Neutral |
| P/E | -1.05 | Sell |
| P/B | 0.64 | Buy |
Latest LVTX news
About
Download (Excel)LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.